Cyclerion Therapeutics (CYCN) Change in Account Payables (2018 - 2025)
Cyclerion Therapeutics (CYCN) posted quarterly Change in Account Payables of $18000.0 for Q3 2025, up 12.5% year-over-year from $16000.0 in Q3 2024, and up 185.71% quarter-over-quarter from -$21000.0 in Q2 2025.
Cyclerion Therapeutics (CYCN) Change in Account Payables (2018 - 2025) Analysis & Trends
Cyclerion Therapeutics' Change in Account Payables history runs 8 years deep, the most recent figure standing at $18000.0 for Q3 2025.
- In Q3 2025, Change in Account Payables rose 12.5% year-over-year to $18000.0; the TTM figure through Sep 2025 stood at $176000.0 (up 220.55% YoY), while the FY2024 annual figure was -$445000.0, up 74.89% from the prior year.
- Change in Account Payables for Q3 2025 stood at $18000.0, up from -$21000.0 in the prior quarter.
- The five-year high for Change in Account Payables was $1.3 million in Q4 2022, with the low at -$2.1 million in Q2 2023.
- The 5-year median for Change in Account Payables is $18000.0 (2025), against an average of -$16105.3.
- The sharpest annual moves came in 2022 and 2023: Change in Account Payables jumped 1379.63% in 2022, then tumbled 931.05% in 2023.
- Cyclerion Therapeutics' Change in Account Payables stood at $965000.0 in 2021, then surged by 37.31% to $1.3 million in 2022, then slumped by 70.94% to $385000.0 in 2023, then slumped by 77.66% to $86000.0 in 2024, then slumped by 79.07% to $18000.0 in 2025.
- Business Quant data shows CYCN's Change in Account Payables at $18000.0 in Q3 2025, -$21000.0 in Q2 2025, and $93000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cyclerion Therapeutics | 12.71 Mn | 9.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 18,000.00 |
| Sep 30, 2025 | 18,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -21,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Dec 31, 2024 | 86,000.00 |
| Dec 31, 2024 | 86,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Sep 30, 2024 | 16,000.00 |
| Jun 30, 2024 | -91,000.00 |
| Jun 30, 2024 | -91,000.00 |
| Mar 31, 2024 | -456,000.00 |
| Mar 31, 2024 | -456,000.00 |
| Dec 31, 2023 | 385,000.00 |
| Dec 31, 2023 | 385,000.00 |
| Sep 30, 2023 | -1.05 Mn |
| Sep 30, 2023 | -1.05 Mn |
| Jun 30, 2023 | -2.06 Mn |
| Jun 30, 2023 | -2.06 Mn |